Hanmi Pharmaceutical Company Limited
Hanmi Pharmaceutical Company Limited
Explore linked clinical trials.15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-09-25 | NCT06234397 | |
| HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) | Congenital Hyperinsulinism, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, Nutritional and Metabolic Diseases, glucose metabolism disease, hyperinsulinism, hypoglycemia, metabolic disease, pancreas disorder | Active, not recruiting | Phase 2 | 2026-08-26 | NCT04732416 | |
| Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Not stated | 2026-08-25 | NCT07784296 | |
| Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-08-17 | NCT07527650 | |
| Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | Active, not recruiting | Phase 1 | 2026-08-12 | NCT05598151 | |
| Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects | Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, intestinal disorder, malabsorption syndrome, short bowel syndrome | Recruiting | Phase 2 | 2026-08-12 | NCT04775706 | |
| A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 3 | 2026-06-30 | NCT07660796 | |
| A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-05-13 | NCT07379333 | |
| A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 1 | 2026-05-04 | NCT07219589 | |
| Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 | 2026-04-08 | NCT07205900 | |
| Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Recruiting | Not applicable | 2026-03-10 | NCT07359105 | |
| Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-03-04 | NCT07449754 | |
| A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers | Healthy | Not yet recruiting | Phase 1 | 2025-12-22 | NCT07297693 | |
| Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2025-12-17 | NCT06724016 | |
| A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease | Fabry Disesase | Recruiting | Phase 1 / Phase 2 | 2025-11-04 | NCT06858397 |